Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2011.0191


Peritoneal recurrence: The challenge in gastric cancer treatment and efforts to prevent.

Dr. John Spiliotis, MD.

Affiliation: Dr. John Spiliotis, Head of Department of Surgery, "METAXA" Cancer Memorial Hospital, Botosi 51, TK 18535, Piraeus, Greece.


Since there is no abstract available we provide the first paragraph.

Standardization of surgery with extended (D2) lymph node dissection and adjuvant systemic treatment with chemotherapy and trastuzumab (Herceptin) for HER2-positive disease in patients with resectable stage II or III gastric cancer, loco-regional and distant recurrence rates and death rates have been reduced. However, peritoneal carcinomatosis still remains the most common cause of treatment failure and death. Peritoneal dissemination is an incurable disease with a median survival of less than 10 months. Can peritoneal recurrence be prevented and how particularly at high-risk patients with advanced serosa invasion (T3,T4) tumor?

(Citation: Gastric & Breast Cancer 2011; 10(4) 232-234)

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €33 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 9 September 2011